145 related articles for article (PubMed ID: 33378277)
1. Long-term application of hydroxychloroquine could not prevent the infection of COVID-19.
Zhu Y; Chen Y; Gong Y; Pan A; Ding H; Fang J; Yu B; Wang B; Ke C; Xu L
J Infect Dev Ctries; 2020 Dec; 14(12):1368-1373. PubMed ID: 33378277
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
5. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
6. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
8. Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine.
Tanaka T; Okamoto M; Matsuo N; Naitou-Nishida Y; Nouno T; Kojima T; Nishii Y; Uchiyashiki Y; Takeoka H; Nagasaki Y
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984543
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
10. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study.
Bhandari S; Singh A; Sharma R; Rankawat G; Banerjee S; Gupta V; Dube A; Kakkar S; Sharma S; Keswani P; Agrawal A; Tak A; Nawal CL
J Assoc Physicians India; 2020 Jun; 68(6):13-19. PubMed ID: 32610873
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine treatment in COVID-19: A descriptive observational analysis of 30 cases from a single center in Wuhan, China.
Xue H; Liu Y; Luo P; Liu X; Qiu L; Liu D; Li J
J Med Virol; 2020 Nov; 92(11):2523-2527. PubMed ID: 32779755
[TBL] [Abstract][Full Text] [Related]
13. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
14. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
Mehta S; Bhandari S; Mehta S
J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
[TBL] [Abstract][Full Text] [Related]
15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
16. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.
Bae S; Ghang B; Kim YJ; Lim JS; Yun SC; Kim YG; Lee SO; Kim SH
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672785
[TBL] [Abstract][Full Text] [Related]
17. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
Purwati ; Miatmoko A; Nasronudin ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Asmarawati TP; Marfiani E; Yulistiani ; Rosyid AN; Wulaningrum PA; Setiawan HW; Siswanto I; Tri Puspaningsih NN
PLoS One; 2021; 16(6):e0252302. PubMed ID: 34143818
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.
Davoodi L; Abedi SM; Salehifar E; Alizadeh-Navaei R; Rouhanizadeh H; Khorasani G; Hosseinimehr SJ
Int J Clin Pract; 2020 Nov; 74(11):e13600. PubMed ID: 32603531
[TBL] [Abstract][Full Text] [Related]
19. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
20. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics.
Liu WD; Chang SY; Lan TY; Lin YC; Kao JH; Liao CH; Tsai MJ; Kuo PH; Huang YS; Wang JT; Sheng WH; Hsieh SC; Chiang BL; Chen YC; Chang SC
J Formos Med Assoc; 2021 May; 120(5):1269-1273. PubMed ID: 32888840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
